CURRICULUM VITAE

DATE PREPARED: November 13, 2009

PART I: General Information

Name: NEZAM HASSAN AFDHAL
Office Address: BETH ISRAEL DEACONESS MED CTR
110 Francis Street
Suite 4A-Liver Research Center
BOSTON, MA 02215 United States
Phone: (617) 632-1069
Email: nafdhal@caregroup.harvard.edu
Fax: (617) 632-1054
Place of Birth: LONDON, ENGLAND

Education:

1981	M.D., ROYAL COLLEGE OF SURGEONS IN IRELAND

Postdoctoral Training:

01/81-	Internship, Medicine and Surgery, Medicine and Surgery, St. Laurences Hospital
01/82-12/84	Resident, Internal Medicine, Internal Medicine, St. Laurences Hospital
01/84-12/87	Fellow, Gastroenterology and Hepatology, Gastroenterology and Hepatology, St. Vincents Hospital
01/87-12/88	Clinical Fellow, Gastroenterology, Gastroenterology, Boston University
01/88-12/89	Research Fellow, Gastroenterology, Gastroenterology, Boston University

Licensure and Certification:

1982	Irish Medical License
1983	Membership, Royal College of Physicians in Ireland
1989	Massachusetts Medical License
1991	Diplomate, American Board of Internal Medicine
1993	Diplomate, ABIM Subspecialty Board in Gastroenterology
1995	Fellow, Royal College of Physicians in Ireland
2006	Certificate of Added Qualification, Transplant Hepatology, ABIM

Academic Appointments:

1989-1994	Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA
1994-2000	Associate Professor of Medicine, Boston University School of

	Medicine, Boston, MA
2000-	Associate Professor of Medicine, Harvard Medical School, Cambridge, MA

Hospital or Affiliated Institution Appointments:

01/89-12/00	Associate Visiting Physician, Boston City Hospital and Boston Medical Center, Boston, MA
01/00-	Physician, Beth Israel Deaconess Medical Center (West), Boston, MA

Other Professional Positions and Major Visiting Appointments:

1991-2000	Consultant Gastroenterologist, East Boston Neighborhood Health Center, East Boston, MA

Hospital and Health Care Organization Clinical Service Responsibilities:

2000-	Chief, Division of Hepatology, Beth Israel Deaconess Medical Center (West)

Major Administrative Responsibilities:

1989-1993	Director, Gastrointestinal Endoscopy, Boston City Hospital
1990-1996	Chief, Section of Gastroenterology and Hepatology, Boston City Hospital
1991-1996	Director, BUSM - Ireland Residency Exchange Program , Boston University School of Medicine
1993	Medical Executive, Boston City Hospital
1993-1994	Chairman, Evans Day Committee, Boston University School of Medicine
1993-1997	Director, Combined Fellowship Training Program, Boston City Hospital, Boston VA Medical Center and University Hospital
1993-2000	Chief of Hepatology, Boston University Medical Center
1995-1997	Director, Clinical Gastroenterology Service, Boston Medical Center
2000-	Chief of Hepatology, Director of Liver Center, Beth Israel Deaconess Medical Center (West)

Major Committee Assignments:

Affiliated Inst

1992	Evans Research Committee for Restructuring Research, Boston University Medical School
1993	Search Committee for Chief, Section of Cardiology, Boston University Medical School
1993	Credentials Committee, Boston City Hospital

1995-1997 Clinical Directors Committee, Boston City Hospital

Regional

1998- Scientific Advisory Board, New England Chapter, American Liver Foundation, American Liver Foundation

1999- Massachusetts State Advisory Board for Hepatitis C, Other

2000- Councilor, Boston Interhospital Liver Group, Boston Interhospital Liver Group

National

1999 Advisor, Fibrosis Markers Panel, NIH HALT-C Trial, National Institutes of Health

2001 NIH Study Section, NIAAA Special Emphasis Panel RFA AA01-004-HIV, HIV and Alcoho, National Institutes of Health

2002 NIH Study Section, Adult to adult living donor liver transplant cohort study , National Institutes of Health

2003 NIH Study Section, Pathogenesis of HCV (RFA DK-03-011), National Institutes of Health

Professional Societies:

1985- Academy of Medicine, Ireland, Member

1986- Irish Society of Gastroenterology, Member

1989- Gastroenterology Research Group, Member

1989- American Gastroenterological Association, Member

1990- Boston Interhospital Liver Group, Member

1990- American Association for Study of Liver Disease, Member

1991- New England Endoscopy Society, Member

1993- AASLD Research Forum , Moderator

1994-1996 AASLD Chairman, Abstract Selection Committee

1994-1997 Program Evaluation Committee, AASLD, Committee Member

1995- British Society of Gastroenterology, Member

1996- European Association for Study of Liver Disease, Member

2000- AASLD Abstract Committee, Member

2002-2005 AASLD Web Site Committee, Member

2006- AASLD, Member, Program Evaluation Ctte

Editorial Boards:

1990- Ad-Hoc Reviewer, Gastroenterology, Hepatology, New England J of Medicine, Annal Internal Medicine, Lancet

1993-1994 Editor, Current Opinion in Gastroenterology, Biliary Diseases

1995- Reviewer, Am J of Gastroenterology, J of Hepatology

1997-2002 Member, Editorial Board of Gastroenterology

1998-2001 Member, Editorial Board of Physicians Home Page

2000-2003 Editor, Gastroenterologyweb.com

2004-	Member, Hepatitis, Index and Reviews
2005-	Member, Editorial Board, Gastroenterology and Hepatology
2007-	Member, J Viral Hepatitis

Awards and Honors:

1977	Norman Rae Gold Medal in Biochemistry, Royal College of Surgeons in Ireland
1980	College of Physicians and Surgeons Prize, Biological Society of the College of Surgeons in Ireland
1986	Medical Research Society Award of UK, United Kingdom
1989	Charles Trey Research Award, American Liver Foundation
1995	Award of Excellence for Clinical Care, American Liver Foundation
2001	Fellow, American College of Gastroenterology
2003	Fullbright Scholarship, Director, US-Egypt Fullbright Program in HCV

Part II: Research, Teaching, and Clinical Contributions

B. Funding Information

1992-1995	Co-P.I., N.I.H., RO1 DK44619, Mucin and non-mucin proteins in gallstone pathogenesis
1994-1997	P.I., N.I.H., RO1 DK 45936, Protein lipid interactions in gallstone pathogenesis
1994-1998	P.I., N.I.H., RO1, Gallbladder mucosal function
1997-2001	Co-P.I., N.I.H., RO1 DK44619, Mucin and non-mucin proteins in gallstone pathogenesis
1999-2003	P.I., N.I.H., RO1 DK45936, Protein lipid interactions in gallstone pathogenesis
1999-2004	National P.I., Company, Multicenter study of PEG-Interferon as maintenance anti-viral therapy in cirrhois secondary to HCV
2000-2007	P.I., Company, COPILOT Study- Phase II Study of Long Term Peg Intron for Patients Who Have Failed to Respond to Rebetron/Interferon with Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C
2001-2006	P.I., N.I.H., UO1 DK 60340, Virahep-C: A Phase III, Multicenter, Open-Label Study to Evaluate the Relative Efficacy of Pegylated Interferon and Ribavirin in African American versus Caucasian Patients with Chronic Hepatitis C and Genotype 1
2002-2007	Project Director, N.I.H., DA16078, The progression of hepatitis C amongst IDU's
2003	P.I., Company, Comparison of Liver Fibrosis Serodiagnostic Panel Results with Histological Evaluations of Liver Fibrosis in Patients Presenting for Liver Biopsy
2003-2004	P.I., Company, A Multiple Rising Dose Study of FK 788 in Subjects with Chronic Hepatitis C Virus Infection
2003	P.I., Company, A Phase I/II, Double-Blind, Dose Escalation Study to

	Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of Val-mCyd in Adults with Chronic Hepatitis C
2003-2006	P.I., Company, A Randomized, Double-Blind Trial of Ldt (Telbivudine) Versus Lamivudine in Adults with Compensated Chronic Hepatitis B
2003-2004	P.I., Company, An Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability, and Activity of ISIS 14803 in Chronic Hepatitis C Patients Undergoing Pegylated Interferon Alfa-2b and Ribavirin Treatment Who Have Not Achieved an Early Virologic Response
2003-2004	P.I., Company, Oral, Ascending, Multi-Dose, Safety, Tolerability and Pharmacokinetics Study of a Caspase Inhibitor IDN-6556 in Patients with Hepatic Impairment
2003-2005	P.I., N.I.H., R21 DK 066765-01, Proteomics and Biomarkers for Hepatocellular Cancer
2005-2010	Co-P.I., N.I.H., U19 A1 066313 , Determinants of chronic liver injury in hepatitis C
2005-2010	P.I., N.I.H., DA 13806, HIV/HCV Antiviral therapy and fibrosis
2006-2010	P.I., N.I.H., 1 U01 AT003571-01 , Clinical Center for Phase 1/2 trials of silymarin in chronic liver disease

D. Report of Teaching

1. Local contributions

a. Medical School Courses

1989-1994 Advances in Dental Medicine, Gastrointestinal and Liver Physiology

		contact time	*prep time*
Lecturer	45 Dental Students	3 hours/week for 16 week(s)	12 hours/week for 16 week(s)

1989-1999 Biology of Disease, Case Discussion Leader

		contact time	*prep time*
Conference Leader	15 Medical Students	4 hours/week for 16 week(s)	12 hours/week for 16 week(s)

1989-1999 Biology of Disease, Biliary Secretion Lecturer

		contact time	*prep time*
Lecturer	65 Medical Students	2 hours/week for 16 week(s)	12 hours/week for 16 week(s)

1990-1999 Microbiology Core Curriculum, Viral Hepatitis

		contact time	*prep time*
Lecturer	65 Medical Students	1 hours/week for 16 week(s)	6 hours/week for 16 week(s)

1994	Correlative Anatomy Course, Liver Blood Flow			
			contact time	*prep time*
	Lecturer	120 Medical Students	1 hours/week for 16 week(s)	6 hours/week for 16 week(s)
2000-	Gastrointestinal Pathophysiology, Human Disease Course, Iron Storage Diseases			
			contact time	*prep time*
	Lecturer	10 Medical Students	1 hours/year for 1 year(s)	5 hours/year for 1 year(s)
2002-	Gastrointestinal pathophysiology, Human Diseases, Chronic LIver Disease Lecture			
			contact time	*prep time*
	Lecturer	140 Medical Students	1 hours/year for 1 year(s)	8 hours/year for 1 year(s)

b. Graduate Medical Courses

1991-2000	Morning Report, Clinical Cases			
			contact time	*prep time*
	Attending	10 Graduate Students 20 Residents	16 hours/week for 52 week(s)	none reported
1991-2000	Emergency Medicine Series, Gastrointestinal Emergencies			
			contact time	*prep time*
	Lecturer	30 Residents 30 Other Students	1 hours/week for 16 week(s)	4 hours/week for 16 week(s)
1991-2000	Interns Conference, Liver Function Tests			
			contact time	*prep time*
	Lecturer	25 Residents 20 Other Students	1 hours/week for 16 week(s)	4 hours/week for 16 week(s)
1993-1997 2002-	Director of Fellowship Program Harvard GI Postgraduate Course			
			contact time	*prep time*
	Lecturer	200 Graduate Students	2 hours/year for 1 year(s)	4 hours/year for 1 year(s)

c. Local Invited Presentations

Grand Rounds

1992 Pathogenesis of Gallstones, Boston Medical Center
Lecturer: 0 participants, 1 hour contact time per day,
12 hours prep time per day

1994 Portal Hypertension, Boston Medical Center
Lecturer: 0 participants, 1 hour contact time per day,
12 hours prep time per day

1997 "An unusual case of ascites", Boston Medical Center
Lecturer: 0 participants, 1 hour contact time per day,
12 hours prep time per day

1998 "Clinical approach to a liver mass", Boston Medical Center
Lecturer: 0 participants, 1 hour contact time per day,
12 hours prep time per day

1999 Evaluation of abnormal liver function tests, Boston Medical Center
Lecturer: 0 participants, 1 hour contact time per day,
12 hours prep time per day

Grand Rounds (surg. & medical)

2000 Surgical and Medical Grand Rounds, Beth Israel Deaconess Medical Center (West)

Grand Rounds (surgical)

1997 Hepatocyte Transplantation, Boston Medical Center
Lecturer: 0 participants, 1 hour contact time per day,
12 hours prep time per day

d. Continuing Medical Education Courses

1991 Advances in Internal Medicine
Lecturer: 160 participants, 1 hour contact time per week,
3 hours prep time per week

1993 Controversies in Internal Medicine
Lecturer: 60 participants, 1 hour contact time per week,
2 hours prep time per week

1994 Controversies in Internal Medicine
Lecturer: 160 participants, 1 hour contact time per week,
2 hours prep time per week

1994-1996 Update in Gastroenterology
Course Director: 50 participants, 12 hours contact time per month,
12 hours prep time per month

1996 Controversies in Internal Medicine
Lecturer: 160 participants, 1 hour contact time per week,
2 hours prep time per week

1996 Update in magnetic resonance imaging
Lecturer: 130 participants, 1 hour contact time per day,
6 hours prep time per day

1996-1999 Retraining in Internal Medicine. Liver and biliary diseases
Lecturer: 6 participants, 3 hours contact time per day,
8 hours prep time per day

1999 Controversies in Internal Medicine
Lecturer: 160 participants, 3 hours contact time per day,
3 hours prep time per day

2001-2006 Update in MRI
Conference Leader: 200 participants, 2 hours contact time per year,
5 hours prep time per year

2003-2008 Update in Gastroenterology
Conference Leader: 300 participants, 4 hours contact time per year,
10 hours prep time per year

2005-2007 Update in Internal Medicine
Lecturer: 300 participants, 3 hours contact time per year,
5 hours prep time per year

e. Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting

1989-1999 2 Fellows for 200 hrs/year, Attending, GI Clinics, Boston U. School Of Medicine

1991-1999 -1 Fellows for 300 hrs/year, Precepting in a lab, Boston U. School Of Medicine

1996-1999 1 Fellows for 200 hrs/year, Attending, Liver Clinic, Boston U. School Of Medicine

2000- 2 Fellows for 400 hrs/year, Attending, Liver Center , Beth Israel Deaconess Medical Center

f. Leadership Roles

1993-1997 Program Director, GI Fellowship Program , Boston City Hospital, Boston University and Boston VA Medical Center
Responsibility: I organized the fellowship program, was the supervisor of 9 Fellows and responsible for curriculum design, observation and teaching.

1993-1999 Coordinator, Student Electives in GI, Boston Medical Center
Responsibility: I helped choose the courses that were offered to the the GI students.

1994-1996 Course Director, Update in Gastroenterology, Boston Medical Center
Responsibility: Oversaw the development and implementation of 20 courses for German Physicians for over 2 years.

1998-1999 Co-Chair, Annual Hepatitis Symposium, Roger Williams Hospital and Boston Medical Center
Responsibility: Gave lectures and directed ethe events of the symposium.

2007- Direector, GI / Liver Core of Medicine residency Program, Beth Israel Deaconess Medical Center
Responsibility: Integration of GI?Liver diseases teaching and research into the IM residency program

2007- Director, Fellowship in Liver Transplantation, Beth Israel Deaconess Medical Center
Responsibility: organization, development and implementation of a new ACGME approved Transplant Hepatology Fellowship.

g. Advisees/Trainees

Training Duration	*Name*	*Current Position*
1991-1999	Niu Niu	Research Associate
1993	Susan Kupferman	Resident
1995-1999	David Nunes	Assistant Professor
1996-1999	Andrew Keaveny	Assistant Professor
1997-1998	XingXiang Cao	Assistant Professor
2003-2008	Bradley Turner	Post Doctoral Student

2. Regional, national, or international contributions

a. Invited Presentations

Regional

1990 GI Grand Rounds, University of Massachusetts Medical Center*[Invited Lecture]*

1992 GI Grand Rounds, Rhode Island Hospital*[Invited Lecture]*

1992 GI Grand Rounds, New England Medical Center*[Invited Lecture]*

1994 M&M Conference, Brigham and Women's Hospital*[Discussant]*

1994 Medical-Surgical Grand Rounds, Beth Israel Hospital*[Invited Lecture]*

1995 Medical Grand Rounds, St. Elizabeth's Hospital*[Invited Lecture]*

1996 GI Grand Rounds, Massachusetts General Hospital*[Invited Lecture]*

1997 GI Research Conference, Beth Israel Hospital*[Invited Lecture]*

1998 GI Grand Rounds, Massachusetts General Hospital*[Invited Lecture]*

1998 Medical Grand Rounds, Dartmouth Hitchcock Medical Center*[Invited Lecture]*

1998 Medical Grand Rounds, Roger Williams Medical Center, Rhode Island*[Invited Lecture]*

1998 Medical Grand Rounds, University of Connecticut Medical Center*[Invited Lecture]*

1999 Medical Grand Rounds, University of Connecticut Medical Center*[Invited Lecture]*

1999 GI Day, Maine Medical Center*[Invited Lecture]*

1999 Medical Grand Rounds, St. Elizabeth's Hospital*[Invited Lecture]*

1999 M&M Conference, Brigham and Women's Hospital*[Discussant]*

2000 HCV Symposium, University of Rochester*[Invited Lecture]*

2000 Case Records, Massachusetts General Hospital*[Case Records]*

2000 ACG Symposium, ACG *[Invited Lecture]*

National

1991 Section of Gastroenterology, Medical College of Virginia*[Visiting Professorship]*

1993 Gallstone lecture, International Gallstone Conference, Washington, DC*[Invited Lecture]*

1999 Occupational and Environmental Medicine, American Association for Occupational and Environmental Medicine, San Antonio, Texas*[Plenary Presentation]*

2000 AGA Course Lecturer, Digestive Disease Week, San Diego, California*[Invited Lecture]*

2005- Invited lecture on therapeutics of hepatitis C in the AASLD Single Topic Conference, AASLD*[Invited Lecture]*

2006 Plenary Presentation: Is Hepatic Fibrosis Reversible, AASLD Single Topic Conference, Basic Research*[Invited Lecture]*

2006 Elsastograghy and Portal hypertension, NIH NIDDK*[Invited Lecture]*

2007- Duke University Grand Rounds and TV presentation -Hepatitis B. GI grand rounds, televised locally and nationally, Duke University*[Invited Lecture]*

International

1993 Hepatology, Irish Liver Foundation, Dublin, Ireland*[Visiting Professorship]*

1995 Gallstone, International Gallstone Conference, Tel Aviv, Israel*[Invited Lecture]*

1995 GI, University of Calgary, Canada*[Visiting Professorship]*

1995 Mitchell Visiting Lecturer, Royal College of Physicians in Ireland*[Invited Lecture]*

1996 Bile Acid Symposium, Canadian Digestive Disease Week*[Invited Lecture]*

1996 GI, Irish Society of Gastroenterology, Coleraine, Ireland*[Visiting Professorship]*

2005- 1st Annual Summit on Viral Hepatitis, Univeristy of Hannover*[Invited Lecture]*

2005- Plenary Speaker at The Pakistan Society of Hepatology, Pakistan

Society of Hepatology*[Plenary Presentation]*

2006- Non Invasive Markers in Liver Disease - pleansy presentation to the 2nd Annual Hepatitis Symposium with 800 attendees., University of Paris*[Invited Lecture]*

2006 2nd Annual Summit on Viral Hepatitis, University of Frankfurt*[Invited Lecture]*

2006 Expert Symposium on Viral Hepatitis, Japanes Society of Hepatology / Schering Plough*[Plenary Presentation]*

2008- Maintenance Therapy for HCV - plenary presentation at the Spanish Society of Hepatology, 1000 attendees, Madrid, Spain, Spanish Society of Gastroenterology and Hepatology*[Plenary Presentation]*

3. Description of Teaching Award(s) Received

1992 VA Teaching Award in Gastroenterology
Boston VA Hospital
1995 Mitchell Lecturer and Medal
Royal College of Physicians in Ireland
1996 Distinguished Lecturer
Irish Society of Gastroenterology

Part III: Bibliography

Original Articles

1. Keatinge AM, Johnson AH, Collins PB, Afdhal N, Lynch D, Lavin JN. Vitamin B1, B2, B6 and C status in the elderly. Ir Med J. 1983;76(12):488-90.
2. Afdhal NH, Smith J, Heffernan S, Doyle JS, Gaffney E. Acute small bowel obstruction secondary to endometriosis: two case reports and a review of the literature. Ir Med J. 1984;77(5):141-3.
3. Afdhal NH, Chman M, Doyle D, Horgan JH. Obstructive sleep apnoea syndrome presenting as cardiac arrhythmia. Ir J Med Sci. 1985;154(3):120-3.
4. Duffy MJ, O'Sullivan F, O'Donoghue D, Afdhal NH, Kelleher D. Ca-19-9, a new marker for gastrointestinal malignancy. Ir J Med Sci. 1985;154(10):385-6.
5. Afdhal NH, Piggott C, Long AA, O'Donoghue DP. Carbohydrate handling by colonic flora--is it pathogenic in the irritable bowel syndrome? Ir J Med Sci. 1986;155(6):197-201.
6. Afdhal NH, Long A, Tobbia I, Cullen A, O'Donoghue DP. Immunohistochemical Cal9-9 in primary colonic polyps and polyps synchronous with colorectal cancer. Gut. 1987;28(5):594-600.

7. McCormick PA, Ramsay N, Afdhal N, Shattuck AG, Hillary IB, Tubridy D, O'Donoghue DP. Serological markers of hepatitis B virus (HBV) infection in alcoholics and hospital controls. Ir J Med Sci. 1988;157(3):77-8.
8. Keane TE, Dillon B, Afdhal NH, McCormack CJ. Conservative management of perforated duodenal ulcer. Br J Surg. 1988;75(6):583-4.
9. Afdhal NH, Kelly J, McCormick PA, O'Donoghue DP. Remission induction in refractory Crohns disease using a high calorie whole diet. JPEN J Parenter Enteral Nutr. 1989;13(4):362-5.
10. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut. 1989;30(12):1704-7.
11. Afdhal NH, Smith BF. Cholesterol crystal nucleation: a decade-long search for the missing link in gallstone pathogenesis. Hepatology. 1990;11(4):699-702.
12. Afdhal NH, Offner GD, Murray FE, Troxler RF, Smith BF. Isolation and characterization of peptides from the protein core of bovine gallbladder mucin. Gastroenterology. 1990;98(6):1633-41.
13. Afdhal NH, Offner GD, Smith BF. Characterization of bovine gallbladder mucin. Amino acid sequences of tryptic peptides from the glycosylated domain of the protein core. Gastroenterology. 1990;99(5):1493-501.
14. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci. 1991;36(4):449-53.
15. O'Brien S, Keogan M, Patchett S, McCormick PA, Afdhal N, Hegarty JE. Postprandial changes in portal haemodynamics in patients with cirrhosis. Gut. 1992;33(3):364-7.
16. Afdhal NH, Gong D, Niu N, Turner B, LaMont JT, Offner GD. Cholesterol cholelithiasis in the prairie dog: role of mucin and nonmucin glycoproteins. Hepatology. 1993;17(4):693-700.
17. Afdhal NH, Niu N, Gantz D, Small DM, Smith BF. Bovine gallbladder mucin accelerates cholesterol monohydrate crystal growth in model bile. Gastroenterology. 1993;104(5):1515-23.
18. Koziel MJ, Dudley D, Afdhal N, Choo QL, Houghton M, Ralston R, Walker BD. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol. 1993;67(12):7522-32.
19. Offner GD, Gong D, Afdhal NH. Identification of a 130-kilodalton human biliary concanavalin A binding protein as aminopeptidase N. Gastroenterology. 1994;106(3):755-62.
20. Nunes DP, Keates AC, Afdhal NH, Offner GD. Bovine gall-bladder mucin contains two distinct tandem repeating sequences: evidence for scavenger receptor cysteine-rich repeats. Biochem J. 1995;310 (Pt 1):41-8.
21. Afdhal NH, Niu N, Nunes DP, Bansil R, Cao XX, Gantz D, Small DM, Offner GD. Mucin-vesicle interactions in model bile: evidence for vesicle aggregation and fusion before cholesterol crystal formation. Hepatology. 1995;22(3):856-65.
22. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M,

Walker BD. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest. 1995;96(5):2311-21.

23. Afdhal NH, Ostrow JD, Koehler R, Niu N, Groen AK, Veis A, Nunes DP, Offner GD. Interaction of bovine gallbladder mucin and calcium-binding protein: effects on calcium phosphate precipitation. Gastroenterology. 1995;109(5):1661-72.
24. Zijlstra AI, Offner GD, Afdhal NH, van Overveld M, Tytgat GN, Groen AK. The pronase resistance of cholesterol-nucleating glycoproteins in human bile. Gastroenterology. 1996;110(6):1926-35.
25. Schroy PC, Wilson S, Afdhal N. Feasibility of high-volume screening sigmoidoscopy using a flexible fiberoptic endoscope and a disposable sheath system. Am J Gastroenterol. 1996;91(7):1331-7.
26. Mac Mathuna P, Siegenberg D, Gibbons D, Gorin D, O'Brien M, Afdhal NA, Chuttani R. The acute and long-term effect of balloon sphincteroplasty on papillary structure in pigs. Gastrointest Endosc. 1996;44(6):650-5.
27. Salomons H, Keaveny AP, Henihan R, Offner G, Sengupta A, Lamorte WW, Afdhal NH. Nitric oxide and gallbladder motility in prairie dogs. Am J Physiol. 1997;272(4 Pt 1):G770-8.
28. Keates AC, Nunes DP, Afdhal NH, Troxler RF, Offner GD. Molecular cloning of a major human gall bladder mucin: complete C-terminal sequence and genomic organization of MUC5B. Biochem J. 1997;324 (Pt 1):295-303.
29. Cao X, Bansil R, Gantz D, Moore EW, Niu N, Afdhal NH. Diffusion behavior of lipid vesicles in entangled polymer solutions. Biophys J. 1997;73(4):1932-9.
30. Afdhal NH, Keaveny AP, Cohen SB, Nunes DP, Maldonado N, O'Brien M, Stone PJ. Urinary assays for desmosine and hydroxylysylpyridinoline in the detection of cirrhosis. J Hepatol. 1997;27(6):993-1002.
31. Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, Houghton M, Walker BD, Koziel MJ. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol. 1998;160(3):1479-88.
32. Offner GD, Nunes DP, Keates AC, Afdhal NH, Troxler RF. The amino-terminal sequence of MUC5B contains conserved multifunctional D domains: implications for tissue-specific mucin functions. Biochem Biophys Res Commun. 1998;251(1):350-5.
33. Cao X, Bansil R, Bhaskar KR, Turner BS, LaMont JT, Niu N, Afdhal NH. pH-dependent conformational change of gastric mucin leads to sol-gel transition. Biophys J. 1999;76(3):1250-8.
34. Nunes DP, Afdhal NH, Offner GD. A recombinant bovine gallbladder mucin polypeptide binds biliary lipids and accelerates cholesterol crystal appearance time. Gastroenterology. 1999;116(4):936-42.
35. Stefan AM, Coulter S, Gray B, LaMorte W, Nikelaeson S, Edge AS, Afdhal NH. Xenogeneic transplantation of porcine hepatocytes into the CCl4 cirrhotic rat model. Cell Transplant. 1999;8(6):649-59.

36. O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, Nunes DP. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol. 2000;114(5):712-8.
37. Guo W, Kurze V, Huber T, Afdhal NH, Beyer K, Hamilton JA. A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems. Biophys J. 2002;83(3):1465-78.
38. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, Xu L, Eng F, Afdhal N, Kalluri R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology. 2003;124(1):147-59.
39. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003;63(23):8312-7.
40. Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J Lipid Res. 2004;45(3):438-47.
41. Wang DQ, Afdhal NH. Genetic analysis of cholesterol gallstone formation: searching for lith (gallstone) genes. Curr Gastroenterol Rep. 2004;6(2):140-50.
42. Afdhal NH, Cao X, Bansil R, Hong Z, Thompson C, Brown B, Wolf D. Interaction of mucin with cholesterol enriched vesicles: role of mucin structural domains. Biomacromolecules. 2004;5(2):269-75.
43. Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Lack of the intestinal Muc1 mucin impairs cholesterol uptake and absorption but not fatty acid uptake in Muc1-/- mice. Am J Physiol Gastrointest Liver Physiol. 2004.
44. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ, Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126(5):1302-11.
45. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, Horsburgh R, Craven D, Sherman KE, Koziel MJ. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology. 2004;40(1):125-32.
46. Wang HH, Afdhal NH, Wang DQ. Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones. Gastroenterology. 2004;127(1):239-49.
47. Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, Koziel MJ, Exley MA. Hepatic CD1d Expression in Hepatitis C Virus Infection and Recognition by Resident Proinflammatory CD1d-Reactive T Cells. J Immunol. 2004;173(3):2159-66.
48. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A, Magder LS, Afdhal NH, Strickland GT. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36(11):752-9.

49. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40(6):1450-8.
50. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19(6):585-592.
51. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol. 2005.
52. Celli J, Gregor B, Turner B, Afdhal NH, Bansil R, Erramilli S. Viscoelastic properties and dynamics of porcine gastric mucin. Biomacromolecules. 2005;6(3):1329-33.
53. Strickland GT, Tanamly MD, Tadros F, Labeeb S, Makld H, Nessim D, Mikhail N, Magder LS, Afdhal NH, Medhat A, Abdel-Hamid M. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liver Dis. 2005;37(7):542-3.
54. Hong Z, Chasan B, Bansil R, Turner BS, Bhaskar KR, Afdhal NH. Atomic Force Microscopy Reveals Aggregation of Gastric Mucin at Low pH. Biomacromolecules. 2005;6(6):3458-66.
55. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH. Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response. Gastroenterology. 2006;130(3):632-638.
56. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH. Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis. Hepatology. 2006;43(4):771-779.
57. Wang HH, Afdhal NH, Wang DQ. Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis leading to biliary hypersecretion in mice. J Lipid Res. 2006;47(4):778-786.
58. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006;43(4):788-95.
59. Kamal SM, Moustafa KN, Chen J, Fehr J, Moneim AA, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdhal NH. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology. 2006;43(5):923-931.
60. Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Evidence That Gallbladder Epithelial Mucin Enhances Cholesterol Cholelithogenesis in MUC1 Transgenic Mice. Gastroenterology. 2006;131(1):210-22.
61. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD, Peginterferon and ribavirin treatment in african american and caucasian american patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470-7.

62. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 2006;44(4):925-935.
63. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS, Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45(1):80-7.
64. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology. 2007;45(3):569-78.
65. Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S, Mikhail N, Magder LS, Afdhal NH, Strickland GT. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007;46(4):620-7.
66. Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis. Hepatology. 2007;45(4):886-94.
67. Cárdenas A, Curry M, Afdhal NH. The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascites. Dig Dis Sci. 2007;52(4):939-40.
68. Celli JP, Turner BS, Afdhal NH, Ewoldt RH, McKinley GH, Bansil R, Erramilli S. Rheology of Gastric Mucin Exhibits a pH-Dependent Sol-Gel Transition. Biomacromolecules. 2007;8(5):1580-1586.
69. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46(2):324-9.
70. Byrnes V, Shi H, Kiryu S, Rofsky NM, Afdhal NH. The Clinical Outcome of Small (
71. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA, Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology. 2007;46(4):971-981.
72. Cardenas A, Lowe R, Oh S, Bodkin S, Kenney T, Lamorte WW, Afdhal NH. Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis. Scand J Gastroenterol. 2007: pp. 1-6.
73. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21(16):2209-16.
74. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-Himes JA, Efler SM,

Davis HL. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007;46(5):1341-9.

75. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-36.
76. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760-767.
77. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum Proteomics and Biomarkers in Hepatocellular Carcinoma and Chronic Liver Disease. Clin Cancer Res. 2008;14(2):470-477.
78. Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallée M, Dev A, Smith-Riggs M, McHutchison JG. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol. 2008;6(2):242-7.
79. Cardenas A, Lowe R, Oh S, Bodkin S, Kenney T, Lamorte WW, Afdhal NH. Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis. Scand J Gastroenterol. 2008;43(3):328-33.
80. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50(1):36-41.
81. Becker L, Salameh W, Sferruzza A, Zhang K, Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2009.
82. Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, Higgins Y, Moore RD, Afdhal N, Torbenson M, Sulkowski M, Thomas DL. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009;48(7):963-72.
83. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24(4):564-8.
84. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med. 2009;360(18):1902-6.
85. Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7(6):696-701.
86. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG, Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin

nonresponders. Hepatology. 2009.

87. Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP, Ewoldt RH, McKinley GH, So P, Erramilli S, Bansil R. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A. 2009;106(34):14321-6.
88. Benhamou Y, Afdhal NH, Nelson DR, Shiffman ML, Halliman DG, Heise J, Chun E, Pockros PJ. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology. 2009;50(3):717-26.
89. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW. Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. J Clin Pharmacol. 2009.

Reviews/Chapters/Editorials

1. Bulger K, Afdhal NH, O'Donoghue DP. A Colorectal Cancer Database. In: Computers in Gastroenterology Vickery R, Editor. London, UK: Springer Verlaken;1988.
2. Afdhal NH, Smith BF. Pathogenesis of Cholesterol Gallstones. Viewpoints on Digestive Disease. 1990;22:13-18.
3. Afdhal NH. Gastrointestinal manifestations of the Acquired Immunodeficiency Syndrome. In: HIV Infection: A Clinical Manual Libman H, Witzburg R, Eds. Boston: Little Brown Publishers;1993. p. 146-159.
4. LaMont JT, Afdhal NH. Cholesterol Gallstone Disease: From Pathogenesis to Prevention. Current Opinion in Gastroenterology. 1994;10:523-5.
5. Afdhal NH, LaMont JT. Pathogenesis of Gallstones. In: Principles and Practices of Gastroenterology and Hepatology, Gitnick G, Ed. Elsevier Science Publishing;1994. p. 561-571.
6. Afdhal NH, Carey MC. New Perspectives on Gallstone Pathogenesis and Prevention. Journal of the Irish Colleges of Physicians and Surgeons. 1995;24:267-78.
7. Afdhal NH, Nunes D. Acalculous cholecystitis. In: Consultations in Gastroenterology Snape WJ, Ed. W.B. Saunders;1996. p. 853-7.
8. Karasik M, Afdhal NH. Biliary Tract Disease. In: Primary Care Medicine Noble J, Ed. St. Louis, MO: Mosby Year Book;1996. p. 605-13.
9. Karasik M, Afdhal NH. Gastrointestinal Manifestations of AIDS. In: HIV Infection: A Clinical Manual Libman H, Witzburg RA, Eds. Boston: Little Brown Publishers;1996. p. 165-80.
10. Keaveny A, Karasik M, Afdhal NH. Pancreatic and Hepatobiliary Infections in AIDS Patients. In: Gastrointestinal Infections LaMont JT, Ed. New York: Marcel Dekker, Inc;1997. p. 361-97.
11. Karasik M, Afdhal NH. Small Bowel and Colonic Infections in AIDS Patients. In:

Gastrointestinal Infections LaMont JT, Ed. New York: Marcel Dekker Inc.;1997. p. 191-247.

12. Afdhal NH. Bacterial, Fungal and Granulomatous Diseases of the Liver. In: Therapy of Digestive Disorders Wolfe MM, Ed. Philadelphia, PA: W.B. Saunders;1999. p. 315-22.
13. Afdhal NH. Crohn's and stones. Am J Gastroenterol. 1999;94(5):1130-2.
14. Keaveny AP, Afdhal NH. A 44 year old woman with sonographic evidence of gallstones. In: Internal Medicine Heffner JE, Sahn SA, Eds. Hanley and Belfus Press;2000. p. 69-71.
15. Afdhal NH. Epidemiology and Pathogenesis of Cholesterol Gallstones. In: Diseases of the Gallbladder and Biliary Tract Afdhal NH, Ed. New York: Marcel Dekker ;2000. p. 127-46.
16. Afdhal NH. Options for Non-responders to Combination Therapy. In: The Non-responding Hepatitis C Patient: Options and Variables, B. Bacon, Ed. Royal Society of Medicine Press;2000. p. 15-28.
17. Afdhal NH. Biliary Tract Disease. In: Primary Care Medicine Noble J, Ed. St. Louis, MO: Mosby Year Book;2001. p. 920-7.
18. Afdhal NH, Geahigan T. Management of the Patient with Chronic Hepatitis. In: Chronic Viral Hepatitis; Diagnosis and Therapeutics, Wu GY, Koff RS, Eds. Humana Press;2001. p. 211-32.
19. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep. 2001;3(1):12-8.
20. Wang DQ, Afdhal NH. Good cholesterol, bad cholesterol: role of oxysterols in biliary tract diseases. Gastroenterology. 2001;121(1):216-8.
21. Byrnes V, Afdhal N. Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor). Curr Treat Options Gastroenterol. 2002;5(2):87-94.
22. Afdhal NH. Diseases of the Gallbladder and Bile Ducts. In: Cecils Textbook of Medicine Goldman L, Ed. Philadelphia, PA: Harcourt Health Science;2003.
23. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology. 2003;37(5):972-4.
24. Kalmowitz BD, Afdhal NH. Maintenance Therapies for Hepatitis C. Current Hepatitis Reports. 2004;3:23-9.
25. Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am. 2004;33(1 Suppl):S25-35.
26. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24 Suppl 2:3-8.
27. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99(6):1160-74.
28. Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem. 2004;50(8):1299-300.
29. Oh S, Afdhal NH. Antiviral therapy for treatment naïve patients with hepatitis C virus. Gastroenterol Clin North Am. 2004;33(3):497-511.

30. Kelleher TB, Afdhal N. Maintenance therapy for chronic hepatitis C. Curr Gastroenterol Rep. 2005;7(1):50-3.
31. Afdhal N. Can serum markers be used to reliably detect liver fibrosis? Nat Clin Pract Gastroenterol Hepatol. 2005;2(3):132-3.
32. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: Patient and treatment considerations. Clin Gastroenterol Hepatol. 2005;3(4):311-8.
33. Curry MP, Afdhal NH. Use of growth factors with antiviral therapy for chronic hepatitis C. Clinics Liver Dis. 2005;9(3):439-51.
34. Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis. 2005;9(4):667-83, vii.
35. Kelleher TB, Afdhal N. Assessment of liver fibrosis in co-infected patients. J Hepatol. 2006;44 Suppl 1:S126-31.
36. Khokar AS, Byrnes V, Afdhal NH. Future therapies for hepatitis C. Current Hepatitis Reports. 2006;5:121-128.
37. Oh S, Afdhal NH. Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Dis Clin North Am. 2006;20(1):99-113.
38. Mueller S, Afdhal NH, Schuppan D. Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology. 2006;130(7):2229-34.
39. McHutchison J, Poynard T, Afdhal N, Fibrosis as an End Point for Clinical Trials in Liver Disease: A Report of the International Fibrosis Group. Clin Gastroenterol Hepatol. 2006.
40. Becker L, Afdhal NH. Nonivasive diagnosis of NASH. In: Nonalcoholic steatohepatitis (NASH) Editors: Bataller R, Caballeria J. Barcelona, Spain: Permanyer Press;2007. p. 111-120.
41. Afdhal NH, Curry M. Technology evaluation: A critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol. 2007;46(4):543-5.
42. Lai M, Afdhal NH. Noninvasive markers of Liver fibrosis. In: Advances in Digestive Diseases. Editor: Howden CW. Bethesda, MD: AGA Institute Press;2007. p. 121 - 134.
43. Malik R, Afdhal N. Stiffness and impedance: the new liver biomarkers. Clin Gastroenterol Hepatol. 2007;5(10):1144-6.
44. Afdhal NH, Esteban R. Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches. Aliment Pharmacol Ther. 2007;26 Suppl 1:1-4.
45. Afdhal NH, McHutchison JG. Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection. Aliment Pharmacol Ther. 2007;26 Suppl 1:29-39.
46. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51.
47. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134(6):1670-81.
48. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B,

Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000-7.

49. Afdhal NH, Manning D. Diagnosis of liver fibrosis in 2008 and beyond. Gastroenterol Clin Biol. 2008;32(6 Suppl 1):88-90.
50. Khokhar A, Afdhal NH. Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med. 2008;121(12 Suppl):S33-44.
51. Manning DS, Afdhal NH. EUS-guided liver biopsy: a procedure looking for an indication. Gastrointest Endosc. 2009;69(3):543-5.

Books, Monographs, and Textbooks

1. N.H. Afdhal. Diseases of the Gallbladder and Biliary Tract. In: Diseases of the Gallbladder and Biliary Tract N.H. Afdhal, Ed. New York: Marcel Dekker Publishers;2000.
2. Afdhal NH. Primary Care Medicine, 3rd Edition. In: Primary Care Medicine, 3rd Edition Noble J, Ed. 3rd St. Louis (MO): Mosby Year Book;2001. p. 900-1026.

Clinical Communications

1. Kline TJ, De las Morenas T, O'Brien M, Smith BF, Afdhal NH. Squamous metaplasia of extrahepatic biliary system in an AIDS patient with cryptosporidia and cholangitis. Dig Dis Sci. 1993;38(5):960-2.
2. Byrnes V, Cárdenas A, Afdhal N, Hanto D. Symptomatic focal nodular hyperplasia during pregnancy: A case report. Ann Hepatol. 2004;3(1):35-7.
3. Cárdenas A, Afdhal NH, Khwaja K. An unusual cause of abdominal pain in a patient with hepatitis C cirrhosis. Gut. 2005;54(4):460.
4. Byrnes V, Afdhal N, Challies T, Greenstein PE. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis. Ann Hepatol. 2006;5(1):56-9.
5. Kamal S, Khalifa K, Moustafa K, Koziel M, El Gohary L, Ramy A, Afdhal N. Reply: Hepatology. 2006;44(4):1051-1052.
6. Lai M, Afdhal N, Challies T. Liver masses and eosinophilia. Liver Int. 2008;28(1):150.
7. Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol. 2008;6(2):255-8.
8. Mehta SH, Lau B, Afdhal NH, Thomas DL. What is the actual role of diagnosis and how to assess it: Reply. J Hepatol. 2009.

NonPrint Materials

1. Afdhal N.H. Complications of laparoscopic cholecystectomy. Up to Date in Medicine;1997.CD-ROM.
2. Afdhal N.H. Colorectal Cancer Screening, Core Curriculum in Medicine. Silver

Platter Publishers;1997.CD-ROM.

3. Afdhal N.H. Abnormal liver function tests for the Primary Care Physician, Core Curriculum in Medicine. Silver Platter Publishers;1997.CD-ROM.
4. Keavney A., Afdhal N.H. Gallstone Ileus. Up to Date in Medicine;1997.CD-ROM.
5. Raj V, Afdhal N.H. Acute Cholangitis, Up to Date in Medicine, Gastroenterology Series. ;1997.CD-ROM.
6. Afdhal N.H. HCV and HIV Co-infection. ;1998.Audiotape from Infectious Disease Association of North America Meeting in Denver, Co.
7. Afdhal N.H. Acalculous cholecystitis. Up to Date in Medicine;1998.CD-ROM.
8. Afdhal N.H. Clinicians Companion I&II: Management of Hepatitis C. Projects in Knowledge;1998.
9. Lowe R., Afdhal N.H. Cholangiocarcinoma. Up to Date in Medicine;1998.CD-ROM.
10. Lucas W., Afdhal N.H. Epidemiology of and risk factors for gallstones. Up to Date in Medicine;1998.CD-ROM.
11. Zakko S., Afdhal N.H. Treatment of acute cholecystitis. Up to Date in Medicine;1998.CD-ROM.
12. Zakko S., Afdhal N.H. Clinical features and diagnosis of acute cholecystitis. Up to Date in Medicine;1998.CD-ROM.
13. Afdhal N.H. Protecting New Jersey's Public Health; What healthcare professionals must know about hepatitis C. ;1999.Videotape, March, 1999.
14. Afdhal N.H. Approach to the patient with incidental gallstones. Up to Date in Medicine;1999.CD-ROM.
15. Lowe R., Afdhal N.H. Cystic diseases of biliary tract. Up to Date in Medicine;1999.CD-ROM.
16. Raj V., Afdhal N.H. Cholangitis in the immunosuppressed patient (AIDS Cholangiopathy). Up to Date in Medicine;1999.CD-ROM.
17. Afdhal N.H., Curry MP. Non-invasive markers of hepatic fibrosis. Up to Date in Medicine;2000.CD-ROM.
18. Afdhal NH. Clinical Implications: Hepatitis in the New Millenium. Predictors of response to HCV. ;2001.ACG CD-ROM.
19. Curry MP, Afdhal NH. Hepatic adenoma. Up to Date in Medicine;2001.CD-ROM.
20. Afdhal NH. AGA GTP Project 2003, Viral Hepatitis Section. ;2003.AGA CD-ROM.
21. Afdhal NH. Hepatic Fibrosis. ;2003.Managing Liver Related Challenges,CD-ROM, AASLD.

Abstracts

1. Gourdin TG, Afdhal NH, Niu N, Smith BF. Calcium augments binding of bilirubin to bovine gallbladder mucin. Hepatology. 1990;12:899.
2. Niu N, Smith BF, Small DM, Afdhal NH. Calcium preferentially accelerates gallbladder mucin induced cholesterol monohydrate crystal nucleation rather than

crystal growth in model bile. Gastroenterology. 1991;(100):781.

3. Karasik MS, Dunzendorfer T, Lee V, Chipkin S, Afdhal NH. Acute hyperglycemia impairs gallbladder and small intestinal motility in normal men. Gastroenterology. 1993;(104):530.
4. Afdhal NH, Niu N, Nunes D, Bansil R, Gantz D, Small DM, Offner GD. Molecular basis of nucleation: differences between slow and fast pro-nucleating proteins. Gastroenterology. 1993;(104):867.
5. Purdum PP, Afdhal NH, Rege R, Moore EW. Effect of mucus gel layer on phospholipid transfer across human cultured gallbladder epithelia. Hepatology. 1994;(20):115.
6. Lataif LE, Niu N, Offner GD, Afdhal NH. Interaction of biliary cholesterol with mucin gels. Gastroenterology. 1994;(106):925A.
7. Karasik M, Dunzendorfer T, Lee V, Chipkin S, Afdhal NH. Acute hyperglycemia impairs gallbladder motility in normal but not diabetic men. American Journal of Gastroenterology. 1995;(90):1606.
8. Kenney TJ, Stefan A, Nunes DP, Offner GD, Nikulasson S, Pouthalakis C and Afdhal NH. Effect of substance P and its receptor antagonist CP-96,345 on systemic arterial and portal pressure in normal and cirrhotic rats. Hepatology. 1995;(22):258.
9. Duzendorfer D, Lee V, Chipkin S, Afdhal NH, Karasik M. HIDA scintigraphy as a test for small intestinal transit: Effect of acute hyperglycemia. American Journal of Gastroenterology. 1995;(90):1631.
10. Offner GD, Nunes DP, Moore EW, Afdhal NH. Prostaglandin E1 stimulates mucin secretion and increases MUC3 mRNA levels in cultured human gallbladder epithelial cells. Hepatology. 1995;(22):110.
11. Offner GD, Nunes DP, Zhang F, McAnany DB, Afdhal NH. Alterations in gallbladder mucin gene expression in patients with cholesterol gallstones. Gastroenterology. 1996;(110):1282A54.
12. Nunes D, Sharma A, Cohen S, Rea C, Offner GD, Apstein M, Afdhal NH. Randomized trial of interferon dose escalation for the treatment of chronic hepatitis C. Gastroenterology. 1996;(110):1281A.
13. Moore EW, Darby G, Afdhal NH. What prevents the gallbladder from digesting itself? Studies of taurochenodeoxycholate toxicity. Gastroenterology. 1996;(110):1268A.
14. Cao X, Niu N, Offner GD, Nunes D, Bansil R, Wolf DE, Afdhal NH. Mucin vesicle interactions are biphasic and depend on mucin glycosylated and non-glycosylated structural domains. Gastroenterology. 1997;(112):1237A.
15. Lowe R, Bodkin S, Kenney T, Afdhal NH. Substance P is not a neuromediator of splanchnic hyperemia or portal hypertension in the cirrhotic rat. Gastroenterology. 1997;(112):1324A.
16. Moore EW, Darby GH, Rege RV, Afdhal NH. What prevents digestion of the gallbladder? Phospholipid protects against the toxic effect of taurochenodeoxycholate but not taurocholate. Gastroenterology. 1997;(112):1337A.
17. Nunes DP, Thim L, Niu N, Afdhal NH, Offner GD. Human spasmolytic polypeptide

(hSP) significantly enhances the cholesterol crystal nucleating properties of mucin. Gastroenterology. 1998;(114):1313A.

18. Keavney AP, Offner GD, Afdhal NH. Inducible nitric oxide is the principal isoform expressed in human gallbladder. Gastroenterology. 1998;(114):526A.
19. Nunes DP, Offner GD, Afdhal NH. Reduced sensitivity of HCV genotype 3 to interferon when co-infected with genotype 1. Gastroenterology. 1998;(114):1314A.
20. Nunes DP, Keaveny A, Gunsalus R, Lebel MD, Edge ASB, Offner GD, Afdhal NH. Serum cytokine profiles in patients with chronic HCV: Effect of interferon treatment. Hepatology. 1998;(28):364A.
21. Tung BY, Afdhal NH, Nunes DP, Thummel KE, Kharasch ED, Croghan AM, Cox PP, Lin M, Kowdley KV. The effect of iron depletion on serum markers of lipid peroxidation and fibrosis in hepatitis C. Hepatology. 1998;(28):568A.
22. Eder MI, Nunes DP, Afdhal NH, Offner GD. TNF-a stimulates mucin secretion, but not mucin synthesis in human gallbladder epithelial cells. Gastroenterology. 1998;(114):1238A.
23. Nunes DP, Anastopolous H, Gordon F, Chopra S, Petruff C, Salomons H, Wilson S, Afdhal NH. Double blind placebo controlled study of interferon versus interferon plus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy. Hepatology. 1999;(30):199A.
24. Keaveny A, Cardenas A, Nunes DP, Edge AE, Afdhal NH. Peripheral TH1 and TH2 cytokine responses in patients with HCV treated with interferon and interferon-ribavirin. Hepatology. 1999;(30):356A.
25. Afdhal NH, Keaveny AP, Nunes DP. Hepatitis C treatment of patients in an urban medical center. Hepatology. 2000;(32):565A.
26. Afdhal NH, Brand M, Apstein A, Cooley J, Hoffman J, Mikolich D, Grace N, O'Connor C, Nunes DP. Randomized controlled trial of interferon A 5mU daily plus ribavirin 1000mg daily versus interferon A 3mU tiw plus ribavirin 1000mg daily in patients with HCV who have never received previous therapy. Hepatology. 2000;(32):363A.
27. Bernard Chasan, Zhenning Hong, Rama Bansil, Bradley Turner, K. Ramakrishnan Bhaskar, Nezam Afdhal. Atomic force microscopy of gastric mucin. Bulletin of the American Physical Society March poster presentation at the annual meeting of the American Physical Society, Seattle, WA. 2001;(46(1)):829.
28. Zhenning Hong, Rama Bansil, Nezam H. Afdhal, K. Ramakrishnan Bhaskar, Bradley S. Turner. Formation and growth of cholesterol crystals in polymer solutions from model bile. Biophysical Journal (Poster presentation at the 45th annual meeting of the Biophysical Society, Boston, MA Feb. 17-21, 2001). 2001;2(80):546a.
29. Afdhal NH, Flamm S, Imperial JA, Malet PF, Tong M, Pappas SC, Campagna J. Pegylated (40kDa) Interferon Alfa-2a (PEGASYS) in Combination with Ribavirin , Mycophenolate Mofetil, Amantadine, or Amantadine plus Ribavirin in Patients that did not Respond to Rebetron Therapy: A Preliminary Report of a Randomized , Multicenter Study. Digestive Disease Week Presentation in Atlanta, Ga. 2001.

30. S.C. Gordon, B.R. Bacon, I.M. Jacobson, M.L. Shiffman, N.H. Afdhal, J.G. McHutchison, T.J. Kwoh, F.A. Dorr. A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C. Hepatology. 2002;36(4):362A.
31. Changqing Yang, Hikaru Sugimoto, Mauricio Giraldo, Nezam Afdhal, Michael Zeisberg, Raghu Kalluri. Bone Morphogenic Protein-7, a Member of the TGF-Beta Superfamily, Accelerates Liver Regeneration After Partial Hepatectomy in Mice. Hepatology. 2002;36(4):470A.
32. Ira Jacobson, Robert S Brown, Jr., Nezam Afdhal, Raymond Rubin, James Spivey, Bradley Freilich, Frederic Regenstein, David Bernstein, Robert Doig, Clifford Brass. Characterictics of HCV Infection in African-Americans: Findings from the WIN-R Trial. Hepatology. 2002;36(4):377A.
33. Ira Jacobson, Robert S Brown, Jr., Nezam Afdhal, Raymond Rubin, James Spivey, Bradley Freilich, Frederick Regenstein, David Bernstein, Robert Doig, Clifford Brass. Clinical Correlates of HCV Genotype and Viral Load: Findings from the WIN-R Trial. Hepatology. 2002;36(4):376A.
34. Nezam H. Afdhal, Bradley Freilich, Martin Black, Robert Levine, Clifford Brass. Comparison of Therapy with Peg-Intron 0.5mcg/kg Versus Colchicine 0.6mg BID in 250 Patients with Cirrhosis and HCV; Interim Data from Copilot. Hepatology. 2002;36(4):312A.
35. Helen H Wang, Nezam H Afdhal, David Q Wang. Increased Fecal Neutral Sterol and Bile Acid Excretion Confers Resistance to Diet-Induced Cholesterol (CH) Cholelithiasis in Gallstone-Resistant AKR Mice. Hepatology. 2002;36(4):460A.
36. John B. Gross, Paul Kwo, Nezam Afdhal, RENEW Investigator Group. Interim Results in the RENEW Trial: A Dose Comparison Study of High-Dose PegInterferon Alfa-2B and Ribavirin for Interferon/Ribavirin Non-Responders with Chronic Hepatitis C. Hepatology. 2002;36(4):359A.
37. Michael Zeisberg, Kyle Kramer, Changqing Yang, Nazia Akhtar, Nezam Afdhal, Raghu Kalluri. Liver Fibrosis: Extracellular Matrix Microenvironment Regulates Hepatocyte Behavior. Hepatology. 2002;36(4):489A.
38. Changqing Yang, Michael Zeisberg, Nezam Afdhal, Raghu Kalluri. New Insights into the Migratory Behavior of Human Hepatocellular Carcinoma HEPG2 Cells. Hepatology. 2002;36(4):449A.
39. Nezam H Afdhal, Christopher B O'Brien, Scott C Oshana, Lisa M Dunkle. Potent Anti-HBV Activity of ACH-126,443 Correlated with 14-Day Pharmacokinetics and Safety: Predictions for Activity Against YMDD Mutant Strains. Hepatology. 2002;36(4):372A.
40. Robert Brown, Ira Jacobson, Nezam Afdhal, Ray Rubin, James Spivey, Frederic Regenstein, David Bernstein, Clifford Brass, Bradley Freilich. Racial/Ethnic Differences in Hematologic Toxicity of Pegylated Interferon and Ribavirin Therapy: Analysis of the Win-R Trial. Hepatology. 2002;36(4):292A.
41. Vijayan Balan, Ira M Jacobson, Robert Brown, Jr., Nezam Afdhal, R Rubin, James Spivey, Bradley Freilich, David E Bernstein, Virender Sharma, Clifford Brass, WIN-R Study Group. Regional and Racial Variation of Hepatitis C Genotypes in the

United States. Hepatology. 2002;36(4):711A.

42. Nezam H. Afdhal, Hiro Masuzaki, Bradley Turner, Imad Nasser, Jeffrey Flier. Transgenic Mice with 11 Beta-Hydroysteroid Dehydrogenase Type 1 Overexpression in Adipocytes Develop Fatty Liver Disease. Hepatology. 2002;36(4):216A.
43. Furqaan Ahmed, Ira M. Jacobson, Robert S. Brown, Jr., Nezam Afdhal, Raymond Rubin, James Spivey, Bradley Freilich, Frederic Regenstein, David Bernstein, Robert Doig, Clifford Brass, WIN-R Study Group. Clinical Significance of Pegylated Interferon Induced Neutropenia: Results from the WIN-R Trial. Gastroenterology. 2003;124(4):A-700.
44. Changqing Yang, Hikaru Sugimoto, Sudhakar Akulppalli, Mauricio Giraldo, Nezam Afdhal, Michael Zeisberg, Raghu Kalluri. Effects of BMP-7 on Liver Regeneration after Partial Hepatectomy in Mice. Gastroenterology. 2003;124(4):A-755.
45. Nezam H. Afdhal, Douglas T. Dieterich, Paul J. Pockros, Eugene R. Schiff, Mitchell L. Shiffman, Mark S. Sulkowski, Teresa Wright, Zobair Younossi, Peter J. Bowers. Epoetin Alfa Treatment of Anemic HCV-infected Patients Allows for Maintenance of Ribavirin Dose, Increases Hemoglobin Levels, and Improves Quality of Life Vs Placebo: A Randomized, Double-blind, Multi-center Study. Gastroenterology. 2003;124(4):A-714.
46. Helen H. Wang, Nezam H. Afdhal, David Q.-H. Wang. Targeted Disruption of Mucin Gene 1 (Muc1) Decreases Susceptibility to Cholesterol (Ch) Gallstone Formation in Mice. Gastroenterology. 2003;124(4):A-698.
47. Changqing Yang, Jiyao Wang, Michael Zeisberg, Mary Soubasakos, Nezam H Afdhal, Raghu Kalluri. Epithelial to Mesenchymal Transition During Liver Fibrosis. Hepatology. 2003;38(4):332A.
48. Nezam h Afdhal, Betty Goon, Kevin Smith, Zobair Younossi. Epoetin Alfa (EPO) Improves and Maintains Health-Related Quality of Life (HRQL) in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study. Hepatology. 2003;38(4):302-3A.
49. Nezam H Afdhal, Angela Klopfer, Linda Tang, Zobair Younossi. Hemoglobin Increase is Independently Associated with Increased Health-Related Quality of Life (HRQL)in Anemic Interferon/Ribavirin (IFN/RBV)-Treated Hepatitis C Virus (HCV)-Infected Patients Treated with Epoetin Alfa. Hepatology. 2003;38(4):312A.
50. Hari S Conjeevaram, David E Kleiner, Nezam Afdhal, Robert S Brown, Michael W Fried, Charles D Howell, Lennox J Jeffers, Nora Terrault, Thelma E Wiley, Chris Cherry, Steve Belle, Jay H Hoofnagle. Race, Insulin Resistance, Visceral Adiposity and Hepatic Steatosis in Genotype 1 Patients with Chronic Hepatitis C. Hepatology. 2003;38(4):347A.
51. Nezam H Afdhal, David Q Wang. The Blockade of Estrogen Action by Fulvestrant (ICI 182,780) Prevents Cholesterol Gallstone Formation in the Mouse. Hepatology. 2003;38(4):195A.
52. John B Gross, Terry M Therneau, Stephanie M Johnson, Paul Y Kwo, Nezam H Afdhal, Steven L Flamm, RENEW Trial Investigators. The RENEW Trial: A National, Multicenter Study of High-Dose Peginterferon Alfa-2B + Ribavirin for

Non-Responders with Hepatitis C. Hepatology. 2003;38(4):312-13A.

53. Stuart C Gordon, Bruce R Bacon, Ira M Jacobson, Mitchell L Shiffman, Nezam H Afdhal, Rosie Z Yu, John G McHutchison, Jesse Kwoh. Treatment of Chronic Hepatitis C with ISIS 14803, An Antisense Inhibitor of HCV, Given for 12 Weeks. Hepatology. 2003;38(4):306-7A.
54. Eric J Lawitz, Norma S Cantu, Mitchell Davis, Nezam Afdhal, Michael Curry, Mark Mailliard, Frank Adams, Naoky Tsai, Andrei Gasic, Tarun Kothari, K.P. Ganeshappa, James Cox, Bruce Silverman, Shailesh C Kadakia. Triple Therapy Compared to Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin for Previous Nonresponders and Relapsers with Chronic Hepatitis C. Hepatology. 2003;38(4):742A.
55. Eric J Lawitz, Norma S Cantu, Mitchell Davis, Nezam Afdhal, Michael Curry, Mark Mailliard, Frank AdamsNaoky TsaiTarun Kothari, K.P. Ganeshappa, James Cox, Bruce Silverman, Shailesh C Kadakia. Triple Therapy Compared to Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin for Treatment Naive Chronic Hepatitis C [Tri-Star Trial]: Final Results. Hepatology. 2003;38(4):636-7A.
56. Eliot Godofsky, Nezam Afdhal, Vinod Rustgi, Lawton Shick, Lael Duncan, Xiao-Jian Zhou, George Chao, Christopher Fang, Barbara Fielman, Maureen Myers, Nathaniel Brown. A Phase I/II Dose Escalation Trial Assessing Tolerance, Pharmacokinetics, and Antiviral Activity of NM283, a Novel Antiviral Treatment for Hepatitis C. Gastroenterology. 2004;126(4):A-681.
57. Brett D. Kalmowitz, Lorenzo Rossaro, Howard P. Monsour Jr., Robert S. Brown Jr., Mohamad A. El-Kurdi, K.R. Bhaskar, Nezam H. Afdhal. Des-Gamma Carboxyprothrombin (PIVKA-II)and Alfafetoprotein in Cirrhosis Secondary to HCV. Gastroenterology. 2004;126(4):A-679.
58. Paul J. Pockros, Mitchell L. Shiffman, Eugene R. Schiff, Nezam H. Afdhal, Mark S. Sulkowski, Zobair Younossi, Teresa Wright, Douglas T. Dieterich, Janice Jenkins, Gerhard J. Leitz, Peter J. Bowers. Long-term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV)Therapy. Gastroenterology. 2004;126(4):A-720.
59. Eugene R Schiff, Paul Pockros, Mitchell L Shiffman, John McHutchison, Robert Gish, Nezam H Afdhal, Manana Makhviladze, Mira Huyghe, David Hecht, Tilman Oltersdorf, David A. Shapiro. Oral IDN-6556, An Anti-Apoptotic Caspase Inhibitor, Lowers Aminotransferases in HCV Patients. Gastroenterology. 2004;126(4):A-668.
60. Helen H. Wang, Nezam H. Afdhal, David Q.H. Wang. Overexpression of Estrogen Receptor Alfa (ER-Alfa)Inhibits the Negative Feedback Regulation of Cholesterol (Ch) Biosynthesis and Increases Newly Synthesized Ch Leading to Biliary Ch Hypersecretion. Gastroenterology. 2004;126(4):A-673.
61. Keyur Patel, David R. Nelson, Nezam Afdhal, Esther Oh, Katie Smith, John G. McHutchison, Don Rockey. Prospective Evaluation of a Serum (FibroSpect II) Panel to Predict Fibrosis in Chronic HCV Patients. Gastroenterology. 2004;126(4):A-708-9.
62. Eric J. Lawitz, Stephen A. Harrison, Norma S. Cantu, Shailesh C. Kadakia, K.P.

Ganeshappa, Frank Adams, Mitchell Davis, Richard Sperling, Naoky Tsai, Andrei Gasic, Tarum Kothari, James Cox, Barry Sanders, Bruce Silverman, Elias Ghandour, Jeffrey Medoff, Vajravel Prasad, Nezam Afdhal, Mark Mailliard, Michael Curry, Alamo Study Group. The Effect of Amantadine on Sustained Virologic Response when Added to Pegylated Interferon Alfa 2b + Weight Based Ribavirin in Previous Nonresponders and Relapsers. Gastroenterology. 2004;126(4):A-697.

63. Valerie M. Byrnes, Honghu Shi, Shigeru Kiryu, Neil M. Rofsky, Nezam H. Afdhal. The Fate of Arterial Enhancing Nodules on MRI in the Cirrhotic Liver. Gastroenterology. 2004;126(4):A-679.
64. Eric J. Lawitz, Norma S. Cantu, Stephen A. Harrison, Shailesh Kadakia, Frank Adams, Mitchell Davis, Richard Sperling, Naoky Tsai, Andrei Gasic, Tarum Kothari, K.P. Ganeshappa, James Cox, Barry Sanders, Bruce Silverman, Elias Ghandour, Jeffrey Medoff, Nezam Afdhal, Mark Mailliard, Michael Curry, Alamo Study Group. The Outcome of Hepatitis C Therapy in African Americans and Hispanics with Persistently Normal Transaminases. Gastroenterology. 2004;126(4):A-696.
65. Nezham Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Bradley Freilich, Kansas Digetsive Diseases, Kanas City, MO; Robert Levine, Syracuse Univeristy, Syracuse, NY; Maritin Black, Temple University, Philadelphia, PA; Robert Brown Jr, Columbia College of Physicians and Surgeons, New York, NY; Howard Monsour, GI and Liver Associates, Granbury, TX; Michael O'Brien, Boston Medical Center, Boston, MA; Clifford Brass, Schering Plough, Kenilworth, NJ. Colchicine versus PEG- Intron long term (CoPilot) trial: Interim analysis of clinical outcomes at year 2. Hepatology. 2004;40(4):239A.
66. Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Eliot Godofsky, Bach & Godofsky, Brandenton, FL; Jules Dienstag, Massachusetts general Hospital, Boston MA; Vinod Rustgi, Metropolitan Research, Fairfax, VA; Lawton Schick, University of Massachusetts Health Center, Worcester, MA; David McEniry, Northwest Medical Specialties, PLLC, Tacoma, WA; Xiao-Jian Zhou, George Chao, Christopher Fang, Barbara Fielman, Maureen Myers, Nathaniel Brown, Idenix Pharmaceuticals, Cambridge, MA. Final phase I/II trial results for NM283, A new polymerase inhibitor for Hepatitis C: Antiviral efficancy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology. 2004;40(4):726A.
67. John G McHutchison, Duke University, Durham, NC; Bruce R Bacon, Saint Louis University School of Medicine, Saint Louis MO; Stuart C Gordon, William Beaumont Hospital, Royal Oak, MI; Nezam H Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira M Jacobson, Cornell University, New York, NY; Andrew Muir, Duke Univeristy, Durham, NC; Arthur M Krieg, Susan Efler, Mohammed Al-Adhami, Heather L Davis, Tess K Schmalback, Coley Pharmaceutical Group, Inc. Wellesley, MA. Human pharmacological activity of a new TLR9 agonist antiviral, CPG 10101 (Actilon). Hepatology The official Journal of the American Association for the Study of Liver Disease. 2004;40(4):697A.
68. Harri S Conjeevaram, Univeristy of Michigan, Ann Arbor, MI; David E Kleiner, Jay

E Everhart, National Institutes of Health, Bethesda, MD; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Robert S Brown, New York-Prebyterian Medical Center, New York, NY; Michael W Fried, Univeristy of North Carolina Chapel Hill, NC; CHarles D Howell, University of Maryland, Baltimore, MD; Lennox J Jeffers, Univeristy of Miami, Miami, FL; Norah Terrault, Univeristy of California, San Francisco, San Francisco, CA; Thelma E. Wiley, Rush Medical Center, Chicago, IL; Christine R Cherry, Abdus S Wahed, Univeristy of Pittsburgh, Pittsburgh, PA; Virahep-C Group. Race, Insulin resistance, visceral, adiposity and hepatic steatosis in patients with chronic hepatitis C. Hepatology. 2004;40(4):443A.

69. Alex S Befer, Saint Louis University, St Louis, MO; Jorge A Marrero, Univeristy of Michigan, Ann Arbor, MI; Ravi S Chari, Vanderbilt Univeristy, Nashville, TN; Lewis Roberts, Mayo Clinic, Rochester, MN; Nezam Afdhal, Harvard University Beth Israel Deaconess Hopsital, Boston, MA; David van Thiel, Loyola Univeristy, Chicago, IL; Adrian M Di Bisceglie, Saint Louis Univeristy, St Louis, MO. The Epidemiology and survival of patients with Hepatocellular Carcinoma in the United States - A prelininary report from the liver cancer network. Hepatology. 2004;40(4):216A.
70. M. Curry, A. Cardenas, N.H. Afdhal. Liver Center, Beth Israel Deaconess Medical Center, Boston, MA, USA. Effect of Maintenance PEG-Intron Therapy on Portal Hypertension and its Complications: Results from the CoPilot Study. Journal of Hepatology. 2005;42(4):40.
71. N. Afdhal, M Rodriguez-Torres, E. Lawitz, E. Godofsky, G. Chao, B. Fielman, S Knox, M. Brown, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Fundacion de Investigacion de Diego, Santurce, PR, USA; Alamo medical Research, San Antonio, TX, USA; Bach & Godofsky, Bradenton, FL, USA; Idenix Pharmaceuticals, Cambridge, MA, USA. Enhanced Antiviral Efficacy For Valopicitabine (NM283) Plus Peg-Interferon in Hepatitis C Patients With HCV Genotype-1 Infection: Results of a Phase IIa Multicenter Trial. Journal of Hepatology. 2005;42(2):39-40.
72. X.J. Zhou, N. Afdhal, E Godofsky, J. Dienstag, V. Rustgi, L. Schick, D. McInery, B.A. Fielman, N.A. Brown. Idenix Pharmaceuticals, Inc, Cambridge, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Bach & Godofsky, Bradenton, FL, USA; Massachusetts general Hospital, Boston, MA, USA; Metropolitan Research, Fairfax, VA, USA; University of Massachusetts Health Center, Worcester, MA, USA; Northwest Medical Specialties, Tacoma, WA, USA. Pharmacokinetics and Pharmacodynamics of Valopicitabine(NM283), A New Nucleoside HCV Polymerase Inhibitor: Results from a phase I/II Dose-Escalation Trial in Patients with HCV-1 Infection. Journal of Hepatology. 2005;42(4):229.
73. V.M. Byrnes, H. Shi, S. Kiryu, N.M. Rofsky, N.H. Afdhal. Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Deparment of Radiology, Beth Israel Deaconess medical Center, Boston, MA, USA. The Fate of Arterial Enhancing Nodules on MRI in the Cirrhotic Liver. Journal of Hepatology. 2005;42(4):90-91.
74. Valerie Byrnes, Anne Miller, Cheryl Weinstein, Erin Hill, Robert Lenkinski, David Alsop, Nezam H. Afdhal. Cerebral Metabolic and neuropsychiatric effects of

pegylated interferon (PIFN) therapy in Hepatitis C. Gastroenterology. 2005;128(4):p-22.

75. Noah T. Zinkin, Hassan H. Otu, Dimitrios Spentzos, Manuel Aivado, meghan Wells, Towia A. Liberman, Nezam H. Afdhal. proteomic Profiling of Hepatocellular carcinoma with Seldi-Tof Mass Spectrometry in Patients with Chronic Liver Disease. Gastroenterology. 2005;128(4):a-30.
76. Paul J. Pockros, Lennox Jeffers, Nezam Afdhal, Zachary D. Goodman, David Nelson, Robert Gish, Rajender Reddy, Robert Reindollar, Maribel Rodiguez-Torres, Sima FarisYoung, Sara Sullivan, Lawrence M. Blatt. Final Result of a double-blind, Placebo-controlled trial of the antibibrotic efficacy of INF Gamma-1b in chronic hepatitis C patients with advanced fibrosis or cirrosis. Gastroenterology. 2005;128(4):p-175.
77. Xiao-Jian Zhou, Nezam Afdhal, Eliot Godofsky, Jules Dienstag; Vinod Rustgi, Lawton Schick. Lael Duncan, Barbara Fielman Constance, George Chao, Nathaniel A. Brown. Pharmacokinetics and Pharmacodynamics of Valopictabine (nm283), a new nucleoside Hcv polymerase inhibitor: results from a phase I/ii dose-escalation trial in patients with Hcv-1 infection. Gastroenterology. 2005;128(4):a-700.
78. Stephen A. Harrison, Chris Fincke, Sangik Oh, Thomas Kelleher, Katie Smith, Nezam Afdhal. Combined Serological and clinical measures enhance the non-invasive diagnosis of advanced fibrosis in NAFLD. Gastroenterology. 2005;128(4):p-227.
79. Sanaa Kamal, Ahmed Al Tawil, Qi HE, Khalifa Sayed, Kheiry El Naggar, Sarah Hakam, Wafaa Saleh, Manal El Sayed, Leonardo Bianchi, Mohamed Madwar, Nezam Afdhal. Long term cohort study of the clinical and histologicalprogression of HCV. Gastroenterology. 2005;128(4):p-195.
80. Helen H. Wang, Nezam H. Afdhal, David Q. Wang. Impaired Gallbladder motility and accelerated cholesterol crystallization and Gallstone formation in mice overexpressing human mucin gene 1 (hmuc1). Gastroenterology. 2005;128(4):p-103.
81. Bruce R. Bacon, John G. McHutchison, Stuart C. Gordon, Nezam H. Afdhal, Ira M. Jacobson, Mitchell Schiffman, Andrew Muir, Arthur M. Krieg, Susan Elfer, Mary Lou Morris, John Whisnant, Mohammed Al-Adhami, Heather Davis, Tess Schmalbach. Safety, Pharmacodynamic (PD) and Pharmacokinetic (PK) profiles of CPG 10101 (Actilon-TM), a novel TLR9 Agonist: Comparison in Normal Volenteers and HCV infected Individuals. Gastroenterology. 2005;128(4):p-91.
82. Maribel Rodiguez-Torres, Eric Lawitz, Eliot Godofsky, Nezam Afdhal, George Chao, Barbara Fielman Constance, Steven Knox, Nathaniel A. Brown. Valopitabine (nm283) alone and in combination with peg-interferon in patients with genotype 1 chronic hepatitis C: Preliminary results from an ongoing phase II, multicenter study. Gastroenterology. 2005;128(4):p-90.
83. John Gross, Stephanie Johnson, Mayo Clinic, Rochester, MN; Paul Kwo, Indiana U. School of Medicine, Indianapolis, IN; Nezam H. Afdhal, beth Israel Deaconess Medical Center, Boston, MA; Stven Flamm, Northwestern U. Department of Medicine, Chicago, IL; Terry Therneau, The RENEW Investigators, Mayo Clinic,

Rochester, MN. Double-Dose PegInterferon Alfa-2B with wieghtbased ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of "RENEW". Hepatology. 2005;vol. 42(No. 4):63A.

84. Asim Khokhar, Rory farnan, Chelsea MacFarlane, BIDMC, Boston, MA; Bruce Bacon, SLU, St. Louis, MO; John McHutchison, Duke Univ medical center, Durham, NC; Nezam Afdhal, beth Israel Deaconess medical Center, Boston, MA. Liver Stiffness and biomarkers: Correlation with cirrhosis, protal hypertension and hepatic synthetic function. hepatology. 2005;42(4):112A.
85. Noah T. Zinkin, Beth Israel Deaconess Medical Center, Boston, MA; Hasan H. Otu, Dimitrios Spentzos, Manuel Aivado, Meghan Wells, Beth Israel Deaconess Medical Center, proteomics Core, Boston, MA; Brett D. Kalmowitz, K.R. Bhaskar, Beth Israel Deaconess Medical Center, Boston, MA; Towia A. Libermann, Beth Israel Deaconess Medical Center, Proteomics Core, Boston, MA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA. A Combined Proteomic and Serologic approach to Diagnosis of Hepatocellular Carcinoma. Hepatology. 2005;vol. 42(no. 4):72A.
86. Xiao-Jian Zhou, Idenix Pharmaceuticals, Inc., Cambridge, MA; Maribel Rodiguez-Torres, Funacion de Investigacion de Diego, Santurce; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Eliot Godofsky, Bach & Godofsky, Bradenton, FL; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Barbara Fielman Constance, George Chao, Steven Knox, Nathaniel A. Brown, Idenix Pharmaceuticals, Cambridge, MA. Asence of effect of Pegylated interferon Alfa-2B on the pharmacokenetics of valopicitabine (NM283) in patients with chronic hepatitis C. Hepatology. 2005;42(4):148A.
87. John G. McHutchinson, Duke Univ, Durham, NC; Bruce R. Bacon, St. Louis Univ Hopsital, St. Louis, MO; Stuart C. Gordon, Henry Ford Hospital, Detroit, MI; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Mitchell Shiffman, Medical College of Richmond Virginia, Richmond, VA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira M. Jacobson, Cornell Univ, New York, NY; Andrew Muir Duke University, Durham, NC; Susan M. Efler, A. Vicari, K. Myette, Nav Ahluwalia, P.P. Murzenok Coley Pharmalbach, Art M. Krieg, Coley Pharmaceutical Group, Ottawa, Canada. Immunophenotyping profile of CPG 10101, a new TLR9 agonist antiviral for hepatitis C. Hepatology. 2005;42(4):148A.
88. Yury Popov, BIDMC, Harvard Medical School, Boston, MA; Sebastian Meuller, Brad Turner, BIDMC, Harvard Medical School, Boston, MA; N. Zinkin, BIDMC, Boston, MA; I. Nasser, H. Masuzaki, BIDMC, Harvard Medical School, Boston, MA; J. Vriereck, Dept. or Neurology and Biophysics, Boston Medical Center, Boston, MA; J. Hamilton, Dept. or Neurology and Biophysics Boston Medical Center, Boston, MA; J. Flier, Nezam Afdhal, Detlef Schuppan, BIDMC, Harvard Medical School, Boston, MA. Mice overexpressing 11B-hydroxysteriod-dehydrogenase (HSD-1) in adipose tisure develop NASH and progressive pericentral fibrosis on a high fat diet. Hepatology. 2005;42(4):168A.
89. Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Andres Cardenas, BIDMC, Boston, MA; Monica Guevara Univ Barcelona, Barcelona, Spain; Peter Gross Unvi Car; Gustav Carus Dresden, Dresden, Germany; Joseph

varbalis, Georgetown Univ Medical center, Washington, DC; Thomas Berl; Robert Schrier, Univ of Colorado health Science Center, Denver, CO; Daniel Bichet Hospital de sacre Courer de Montreal, Montreal Canada; Lynn Wagoner, Univ of Cinncinnati Heart and Vascular Center. Cincinnati, OH; John Ouyang; Cesare Orlandi; Frank Czerwiec, Otsuka Maryland Research Institute, Rockville, MD. Randomized Placebo-Controlled trial of Tolvaptan, a novel v2-receptor antagonist, in hyponatremia: results of the salt 2 trial with emphasis on efficacy and safety in cirrohosis. hepatology. 2005;42(4):172A.

90. Christopher O'brien, University of Miami, Miami, FL; Eliot Godofsky, Bach & Godofsky, Brandenton, FL; Maribel Rodriguez-Torres, Fundacion de Investigacion de diego, Sanurce, Puerto Rico; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; S.C. Pappas, St. Luke's Episcopal Hospital. Randomized trial of valopicitabine (NM283), alone or with Peg-Interferon, VS. Retreatment with peg-interferon plus ribavirin (Peginf/rbv) in hepatitis C patients with pervious non-response to pegifn/rbv: first interi, results. Hepatology. 2005;vol. 42(no. 4):69A.
91. John McHutchinson, Duke Univeristy, Durham, NC; Bruce Bacon, St. Louis University Hospital, St. Louis, MO; Stuart C. Gordon, Henry Ford Hospital, Detroit, MI; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Michell Shiffman, Medical College of Virginia, Richmond, VA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira Jacobson, Cornell University, New York, NY; Andrew Muir, Duke Univeristy, Duram, NC; Susan Elfer, Coley Pharmaceutical Group, Ottawa, Canada; Mohammed Al-Adhami, Coley Pharmaceuticals Group, Wellesley, MA; Heather Davis, Coley Pharmaceutical Group, Ottawa, Canada; Tess Schmalbach, Coley Pharmaceutical Group, Wellesley, MA. Relationship of HCV RNA responses to CPG 10101, A TLR9 Agonist: Pharmacodynamics and patient characteristics. Hepatology. 2005;42(4):75A.
92. Ira M. Jacobson, Weill Medical College of Cornell University, new York, NY; Robert S. Brown, Columbia University College of Physicians & Surgeons, New York, NY; Bradley Freilich, Baptist Medical Center, Kansas City, MO; Nezam Afdhal, beth Israel Deaconess Medical Center, Boston, MA; Pauk Kwo, Indian University School of Medicine, Indianapolis, IN; John Santoro, Atlantic Gastroenterology Associates, Egg Harbor Township, NJ; Scott becker, Austin Gastroenterology, PA, Austin, TX; Adil Wakil, California Pacific Medical Center, San Francisco, CA; David Pound, Indianapolis Gastroenterology Rsch, Indianapolis, IN; Eliot Godofsky, Bach and Godofsky, MD PA, Bradenton, FL; Robert Strauss, Northwest Georgia Gastroenterology Associates, P.C. Marietta, GA; David Bernstein, North Shore University Hospital, Mahasset, NY; Steven Flamm, Northwestern Memorial Hospital, Chicago, IL; Natrajan Bala, Gastroenterology consultants, Houston, TX; Victor Araya, Albert Einstein Medical Center, Philadelphia, PA; Mitchell Davis, SOuth Florida center of Gastroenterology, P.A., Wellington, FL; Howard Monsour, Liver Specialists of Texas, Houston, TX; John Vierling, Cedars-Sinai Medical Center, Los Angeles, CA; Fredric Regenstein, Tulane University Medical School, New Orleans, LA; Vijay Balan, Mayo Clinic, Phoenix, AZ; Michael Dragutsky, GI Consultants of the Midshouth, Memphis; TN; Michael Epstein, Digestive Disorders Associates Annapolis, MD; Robert W. Herring, Nashville, TN; Raymond Rubin, Atlanta Gastroenterology Assoc, Atlanta,

GA; Greg Galler, Kelsey-Seubold Clinic, Houston, TX; Mary Pat Pauly, Kaiser Permanente, Sacramento, CA; Louis H. Griffel; Clifford A. Brass, Schering-Plough Research Institute, kenilworth, NJ; the WIN-R S. Group, kenilworth, NJ. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, A US community based trial. Hepatology. 2005;42(4):77A.

93. Hari S. Conjeevaram, University of Michigan, Ann Arbor, MI; Michael W. Fried, University of North Carolina, Chapel Hill, NC; Lennox J. Jeffers, VA Medical Center, Miami, FL; Norah Terrault, UCSF, San Francisco, CA; Thelma E. Wiley-Lucas, Rush University Medical Center, Chicago, IL; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Robert S. Brown Jr, New York Presbyterian-Columbia Presbyterian Center, New York, NY; Steve H. Belle, University of Pittsberg, Pittsburgh, PA; Patricia R. Robuck, NIDDK, NIH, Bethesda, MD; Charles D. Howell, University of Maryland, Baltimore, MD. Peginterferon Alfa-2A and ribavirin in African american and caucasian patients with chronic hepatitis C, Genotype 1. hepatology. 2005;42(4):90A.
94. Michelle Lai, Benjamin Hyatt, BIDMC, Boston, MA; Nezam Afdhal, BIDMC, Boston, MA. Role of liver Biopsy in Patients with Normal ALT and High HBV DNA. Hepatology. 2005;42(4):188A.
95. Malik R, Farnan R, Lai M, Freitag H, Schuppan D, Afdhal NH. Comparison of Fibroscan, APRI, AST/ALT and Clinical Signs as non invasive predictors of Cirrhosis. Hepatology. 2007;46:428A.
96. Afdhal NH, McHutchison JG, Shiffman ML, Rodrigues Torres, M, Dusheioko GM, Sigal S, White S, Blackman N, Cambell F, Dickens T. Eltrombopag raises platelet count in 2 weeks in patients with HCv and significant thrombocytopenia. Hepatology. 2007;46:252A.
97. Byrnes,VM, Miller, A, Hill,E, Weinstein, david Alsop, Lenkinski, R.E, Afdhal, NH, The Cerebral Metabolic and Cognitive Effects of Pegylated interferon (PIFN) and Hepatitis C Viral (HCV) Clearance. Hepatology. 2007;46:380A.
98. Shah MB,Brown RS, Barski T, Freilich B, Levine RA, Afdhal NH. Tolerability of low-dose peginterferon alfa-2B in hepatitis C patients with Cirrhosis: Results from the copilot trial. Hepatology. 2007;46:825A.
99. Afdhal, NH, Manns MP, Lennox JJ, Nguyen T, Berg T, Dalekos GN, Trepo C, Roberts SK, Prieto M, Sorbel J, Anderson J, Mondou E, Rousseau F. The Antiviral Response to Tenofovir Disoproxil Fumarate (TDF) Is Comparable in Lamivudine (LAM)-Naive and LAM-Experienced Subjects treated for chronic Hepatitis B (CHB). Gastroenterology. 2008;134:A809.
100. Afdhal NH, Levine R, Brown R Jr.,Freilich B, O'brien M, Brass C. Colchicine Versus Peg-Interferon Alfa 2B long term Therapy: Results of the 4 year copilot trial. Hepatology. 2008;48:S4.
101. Malik R, Lai M, BhaskarIN, Curry M, Schuppan D, Afdhal NH. Identification of Biomakers that measure disease activity in patients with nonalcoholic fatty liver disease. Hepatology. 2008;48:s355.
102. Popov Y, Zaks J, Grall F, Liebermann T, Afdhal NH, Schuppan D. T Cell Derived

Membrane Microparticles containing Emmprin Induce Profibrolytic Activation in Hepatic Stellate Cells. Hepatology. 2008;46:717A.